Does Selenium Thyroid Antibodies Randomized Trial work?

The current Migaku evidence database contains 2 reusable source documents for Selenium Thyroid Antibodies Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Combination therapy significantly reduced TSH levels compared with Sel monotherapy (SMD -1.26; 95% CI -1.51 to -1.00; p 2 = 0%), and TSA suggested that this finding may be robust, although the evidence is limited by the small number of studies. [Stanchev P (2026); evidence level 1] - TgAb levels were also significantly reduced (SMD -0.51; 95% CI -0.78 to -0.24; p 2 = 0%); however, TSA indicated a potential risk of type I error. [Stanchev P (2026); evidence level 1] - Conclusions : MI combined with Sel was associated with a significant reduction in TSH levels compared with Sel alone in patients with HT and subclinical hypothyroidism, suggesting a potential therapeutic benefit. [Stanchev P (2026); evidence level 1] - Introduction : Hashimoto's thyroiditis (HT) is the leading cause of hypothyroidism in iodine-sufficient regions and often presents with subclinical hypothyroidism. [Stanchev P (2026); evidence level 1] - Across studies, PBM was associated with reductions in thyroid autoantibodies, improvements in thyroid hormone indices, and decreases in LT4 dose requirements. [Berisha-Muharremi V (2026); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.